Severe mental illness is associated with increased mortality and severe course of COVID-19.
COVID-19
bipolar disorder
depression
respiratory infection
schizophrenia
unfavourable outcome
Journal
Acta psychiatrica Scandinavica
ISSN: 1600-0447
Titre abrégé: Acta Psychiatr Scand
Pays: United States
ID NLM: 0370364
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
12
04
2021
received:
04
03
2021
accepted:
20
04
2021
pubmed:
25
4
2021
medline:
24
7
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
Psychiatric disorders have been associated with unfavourable outcome following respiratory infections. Whether this also applies to coronavirus disease 2019 (COVID-19) has been scarcely investigated. Using the Danish administrative databases, we identified all patients with a positive real-time reverse transcription-polymerase chain reaction test for COVID-19 in Denmark up to and including 2 January 2021. Multivariable cox regression was used to calculate 30-day absolute risk and average risk ratio (ARR) for the composite end point of death from any cause and severe COVID-19 associated with psychiatric disorders, defined using both hospital diagnoses and redemption of psychotropic drugs. We included 144,321 patients with COVID-19. Compared with patients without psychiatric disorders, the standardized ARR of the composite outcome was significantly increased for patients with severe mental illness including schizophrenia spectrum disorders 2.43 (95% confidence interval [CI], 1.79-3.07), bipolar disorder 2.11 (95% CI, 1.25-2.97), unipolar depression 1.70 (95% CI, 1.38-2.02), and for patients who redeemed psychotropic drugs 1.70 (95% CI, 1.48-1.92). No association was found for patients with other psychiatric disorders 1.13 (95% CI, 0.86-1.38). Similar results were seen with the outcomes of death or severe COVID-19. Among the different psychiatric subgroups, patients with schizophrenia spectrum disorders had the highest 30-day absolute risk for the composite outcome 3.1% (95% CI, 2.3-3.9%), death 1.2% (95% CI, 0.4-2.0%) and severe COVID-19 2.7% (95% CI, 1.9-3.6%). Schizophrenia spectrum disorders, bipolar disorder, unipolar depression and psychotropic drug redemption are associated with unfavourable outcomes in patients with COVID-19.
Identifiants
pubmed: 33894064
doi: 10.1111/acps.13309
pmc: PMC8250986
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-91Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
JAMA Psychiatry. 2013 Sep;70(9):931-9
pubmed: 23863861
J Affect Disord. 2016 Jun;197:167-74
pubmed: 26994434
Clin Infect Dis. 2021 Dec 6;73(11):e4025-e4030
pubmed: 32634827
Acta Psychiatr Scand. 2007 Nov;116(5):317-33
pubmed: 17919153
Am J Psychiatry. 2005 Feb;162(2):370-6
pubmed: 15677603
Acta Psychiatr Scand. 2020 Jul;142(1):70-71
pubmed: 32323297
JAMA. 2020 Jul 14;324(2):168-177
pubmed: 32558877
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
World Psychiatry. 2015 Jun;14(2):119-36
pubmed: 26043321
Acta Psychiatr Scand. 2019 Oct;140(4):340-348
pubmed: 31355419
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Acta Psychiatr Scand. 2019 Jun;139(6):558-571
pubmed: 30844079
Lancet. 2019 Nov 16;394(10211):1827-1835
pubmed: 31668728
Schizophr Bull. 2011 Sep;37(5):1088-94
pubmed: 20339152
J Am Heart Assoc. 2019 Aug 20;8(16):e012708
pubmed: 31423870
Am J Psychiatry. 2015 Aug 1;172(8):776-83
pubmed: 25698437
Resuscitation. 2019 Oct;143:180-188
pubmed: 31325557
Mol Psychiatry. 2021 Jan;26(1):30-39
pubmed: 32929211
Clin Epidemiol. 2019 Jul 12;11:563-591
pubmed: 31372058
FEMS Immunol Med Microbiol. 2006 Aug;47(3):330-42
pubmed: 16872369
Brain Behav Immun Health. 2020 Jul;6:100097
pubmed: 32835296
Alzheimers Dement. 2020 Nov;16(11):1571-1581
pubmed: 32789951
Nat Rev Endocrinol. 2021 Mar;17(3):135-149
pubmed: 33479538
Resuscitation. 2020 Aug;153:10-19
pubmed: 32446792
Lancet Psychiatry. 2020 Dec;7(12):1025-1031
pubmed: 32950066
World Psychiatry. 2021 Feb;20(1):124-130
pubmed: 33026219
Acta Psychiatr Scand. 2020 Jul;142(1):66-67
pubmed: 32415875
Scand J Public Health. 2011 Jul;39(7 Suppl):91-4
pubmed: 21775362
World Psychiatry. 2011 Jun;10(2):138-51
pubmed: 21633691
Scand J Public Health. 2011 Jul;39(7 Suppl):54-7
pubmed: 21775352
Scand J Public Health. 2011 Jul;39(7 Suppl):103-5
pubmed: 21775365
Scand J Public Health. 2011 Jul;39(7 Suppl):38-41
pubmed: 21775349
Acta Psychiatr Scand. 2002 Mar;105(3):164-72
pubmed: 11939969
J Clin Psychopharmacol. 2016 Aug;36(4):355-71
pubmed: 27307187
Euro Surveill. 2014 Jan 09;19(1):
pubmed: 24434175
Am J Psychiatry. 2013 Mar;170(3):324-33
pubmed: 23318474